|Podcasts|July 16, 2013
What does RBM mean to Sanofi's CRAs and site monitors
Lori Convy, Assistant Director, Clinical Research Monitoring, Sanofi discusses what risk-based monitoring mean to Sanofi's CRAs and site monitors?
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation
2
ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots
3
Beyond Eligibility: Making Trust and Behavioral Readiness Actionable in Clinical Trial Recruitment
4
AI-Enabled Systems Medicine: From Digital Promise to Clinical Operating Model
5